Veterinary Diagnostics Market Size & Share 2026-2035

Veterinary Diagnostics Market Size

The global veterinary diagnostics market is valued at USD 5.3 billion in 2025 and is projected to reach USD 12.6 billion by 2035, expanding at a 9.1% CAGR.

The market comprises instruments, consumables, and software used to detect, characterize, and monitor disease in companion, farm, and equine animals across clinics, reference laboratories, public laboratories, and home-care settings. It spans clinical biochemistry, hematology, urinalysis, immunodiagnostics, molecular testing, and diagnostic imaging, including AI-assisted interpretation.

Demand is supported by two different care models. Companion-animal diagnostics are increasingly shaped by preventive care, chronic-disease monitoring, and owners' willingness to pursue workups. Mars reported that more than one billion pets are kept globally and that more than 56% of people are pet parents. ^{[1]Mars, Incorporated - Mars Unveils World's Largest Pet Parent Study, October 2024 - mars.com} FEDIAF reported that 139 million European households had at least one pet in 2025. Farm-animal testing follows a more institutional logic: surveillance, biosecurity, food safety, and movement controls can require testing even when individual producers face cost pressure. FAO estimates that 60% of human infectious diseases originate in animals and that 75% of emerging infectious diseases are zoonotic. ^{[2]Food and Agriculture Organization of the United Nations - Zoonoses - fao.org}

The commercial ecosystem links biological and reagent suppliers, analyzer and imaging manufacturers, kit producers, practice-management and interpretation software providers, distributors, veterinary practices, reference laboratories, and public animal-health networks. Installed instruments create recurring demand for proprietary cartridges, reagents, and service contracts. This attachment model makes placement economics as important as the initial capital sale, while cloud-connected instruments add a data layer that supports result delivery, longitudinal records, and AI-enabled interpretation.

Technology is shifting diagnostic work toward more decentralized and information-rich workflows. Miniaturized PCR, isothermal amplification, lateral-flow formats, and quantitative immunoassays widen the range of tests that can be performed near the patient. At the same time, advanced sequencing and centralized laboratories retain an advantage in complex outbreak investigation and broad pathogen discovery. Royal GD's integration of PathoSense nanopore sequencing illustrates the latter model: one assay can investigate viruses and bacteria without requiring an initial pathogen hypothesis.

AI has the clearest near-term role in image and workflow interpretation rather than replacing clinical accountability. A 2025 review found sustained growth in veterinary deep-learning applications from 2013 through 2024, with radiography and cytology each representing 33% of applied use cases. The American College of Veterinary Radiology supports ethical, transparent AI use in diagnostic imaging and radiation oncology. The practical implication is that AI can extend specialist capacity and standardize first-pass interpretation, but its value depends on image quality, clinical context, validation, and integration into the practice workflow.

Regulation sets both a quality threshold and episodic sources of volume. In the United States, APHIS updated its diagnostic-product licensing guidance in January 2024. Its April 2024 Federal Order required Influenza A testing at approved laboratories before interstate movement of dairy cattle, converting surveillance into a mandatory testing workflow. In Europe, Regulation (EU) 2016/429 harmonizes animal-health surveillance and control obligations across Member States. WOAH diagnostic guidance and internationally recognized laboratory methods remain important for trade-sensitive diseases, including African swine fever.

Pricing and adoption therefore vary by setting. Clinics favor tests that influence a same-visit treatment decision; reference laboratories concentrate methods requiring broader menus, specialist interpretation, or rigorous validation. Emerging markets can have substantial disease exposure but lower diagnostic monetization when owner spending, insurance penetration, laboratory access, or veterinary density is limited. The resulting opportunity is not simply broader animal ownership: it is the conversion of animal populations into repeated, clinically actionable test use.

The pivotal commercial contest is over where clinical decisions occur. Central laboratories retain the advantage in high-complexity testing, whereas point-of-care platforms win when turnaround changes immediate treatment, referral, or isolation decisions. Suppliers that pair dependable analyzers with recurring consumables, connected software, and credible clinical validation can increase testing frequency without forcing every practice to build laboratory-scale capability. Mandatory surveillance can accelerate molecular demand, but it should not be conflated with enduring clinic utilization; the latter depends on workflow fit, reimbursement, and client authorization.

Key Drivers

Growing trend of adopting pet animals

A larger companion-animal base broadens the pool of animals entering wellness, acute-care, and chronic-disease pathways. The scale of ownership is evident in Europe's 139 million pet-owning households and in Mars's finding that 47% of pet parents surveyed were first-time owners. New owners can be especially important to diagnostics because their care habits are established alongside digital booking, preventive plans, and clinic recommendations. The economic effect is cumulative: each additional animal is a potential source of repeated chemistry, hematology, parasite, and age-related monitoring rather than a one-time procedure.

Rising prevalence of foodborne and zoonotic diseases

Zoonotic and foodborne disease risks sustain demand for surveillance across the food-animal chain. WHO's estimates for 42 foodborne hazards identified 866 million illnesses, 1.52 million deaths, and 57.1 million disability-adjusted life years globally. The EU's 2023 zoonoses report identified campylobacteriosis and salmonellosis as the two most frequently reported zoonoses in humans. For laboratories and producers, diagnostics are not merely a clinical service: they support detection, movement decisions, outbreak response, and evidence for control measures. Disease events can create abrupt testing peaks, particularly for validated molecular assays, while endemic surveillance underpins a steadier base of demand.

Favorable government initiatives

Public programs increase demand when they specify testing methods, fund laboratory networks, or require proof of disease status. The U.S. dairy-cattle order is a direct example of regulatory requirements generating PCR workflow volume. ^{[3]USDA APHIS - Federal Order Requiring Testing for and Reporting of HPAI in Livestock, April 2024 - aphis.usda.gov} Europe's Animal Health Law provides a harmonized framework for surveillance, notification, and control, while WOAH laboratory guidance supports comparable approaches for internationally significant diseases. These initiatives also shape product competition: suppliers must demonstrate validation, traceability, and deployment capability to participate in public procurement and regulated laboratory networks.

Advancements in companion diagnostics

Decentralized technology is expanding the range of decisions that can be made during a consultation. Veterinary point-of-care formats increasingly combine portability with quantitative or molecular capability. Zoetis introduced Vetscan OptiCell as a cartridge-based, AI-powered hematology analyzer designed to return a complete blood count in under five minutes ^{[4]Zoetis - Zoetis Announces Global Launch of Vetscan OptiCell at VMX 2025, December 2024 - news.zoetis.com}, while bioMérieux introduced VETFIRE for simultaneous detection of seven equine respiratory pathogens in under 20 minutes. Such systems can reduce delays between sample collection and treatment choice, but their commercial success depends on whether the test is sufficiently reliable, easy to operate, and affordable for the practice's patient mix.

Increasing adoption of pet insurance

Insurance changes the authorization environment by reducing the immediate financial burden of a diagnostic workup. NAPHIA reported USD 5.2 billion in North American pet insurance written premium and 7.03 million insured pets at year-end 2024. AVMA reported that U.S. premium volume reached USD 4.74 billion in 2024 and that 6.4 million pets were insured. Insurance does not automatically create demand for every assay, but it can make advanced imaging, pathology, and molecular confirmation more accessible when a veterinarian considers them clinically useful. Its influence is strongest where claims processes and benefit design do not add friction at the point of care.

Key Restraints

Prohibitive cost associated with animal tests

Capital equipment, proprietary consumables, and specialist interpretation costs limit in-house adoption and client acceptance. The constraint is most acute for small practices that cannot reliably spread an analyzer's fixed cost across enough tests, and for food-animal operations where diagnostic cost must be weighed against animal value and herd-scale economics. The result can be a split market: referral centers deploy premium molecular, imaging, and pathology services, while general practices rely on rapid screens or send-out testing. Leasing, reagent-rental, and managed-service arrangements can lower the entry barrier, but they do not remove the need for consistent test volumes.

Low out-of-pocket expenditure on veterinary care

In markets with limited insurance and lower preventive-care spending, pet population growth does not immediately translate into equivalent diagnostic revenue. Owners may seek treatment only after disease becomes visible, while clinicians may face lower acceptance of broad workups. This limits routine screening and favors lower-cost formats over complex panels. The restraint is structural rather than purely technological: adoption rises when affordability, veterinary access, client education, and confidence in the clinical value of testing develop together.

Point-of-care platforms can mitigate friction when a rapid result avoids a follow-up visit, supports same-day treatment, or reduces the need for a referral. They are less compelling when the result requires complex confirmation or when cost sensitivity suppresses the initial consultation. Suppliers should therefore segment offerings by decision urgency and practice throughput, rather than assume that decentralization will displace reference laboratories universally.

Veterinary Diagnostics Market Segment Analysis

By Product

Consumables lead because each installed analyzer generates recurring reagent, cartridge, and assay-kit demand. IDEXX reported USD 1.303 billion of VetLab consumables revenue in 2024, up 12% year over year. ^{[5]IDEXX Laboratories - Fourth Quarter and Full Year 2024 Results, February 2025 - idexx.com} The category's economics reward suppliers that sustain analyzer uptime, menu breadth, and test frequency. Instruments remain essential because they establish the installed base, but their slower 8.7% CAGR reflects the capital-purchase cycle. Software's 9.7% CAGR reflects the growing value of connectivity, workflow integration, image interpretation, and results management around that installed base.

By Modality

Lab-based testing remains the larger modality because specialist pathology, culture and susceptibility testing, advanced molecular workflows, and broad panels benefit from centralized expertise and quality controls. Point-of-care testing grows slightly faster as clinics value immediate results in acute and routine workflows. These modalities are complementary: a practical clinic model often uses in-house testing for rapid triage and monitoring, then refers complex samples to a laboratory.

By Technology

Clinical biochemistry leads because it is embedded in wellness, pre-anesthetic, emergency, and chronic-care routines. Its subsegments are glucose monitoring at USD 634.9 million in 2025 and 9.1% CAGR; blood gas and electrolyte analysis at USD 411.0 million and 9.7%; and other tests at USD 319.5 million and 8.7%.

Immunodiagnostics is anchored by ELISA, which represents USD 855.7 million in 2025, or 84.0% of the segment, and grows at 8.7%. Lateral-flow assays account for USD 89.1 million and grow at 9.3%; immunoassay analyzers represent USD 31.6 million and grow at 9.1%; other immunodiagnostic tests are USD 42.3 million and grow at 8.5%. ELISA's installed base and surveillance utility preserve its scale, while improved rapid formats broaden decentralized use.

Molecular diagnostics grows at 9.6%, supported by outbreak surveillance and the need for specific pathogen identification. PCR is USD 591.1 million in 2025, or 64.1% of the segment, and grows at 9.7%; microarrays are USD 203.9 million and grow at 9.9%; other molecular tests are USD 127.8 million and grow at 8.5%. WOAH guidance underscores the centrality of validated molecular methods for priority animal diseases. ^{[6]World Organisation for Animal Health - Addressing African Swine Fever: Laboratory Guidelines, 2024 - woah.org}

Hematology, urinalysis, and imaging serve different points in the clinical pathway. Hematology reaches USD 1,234.6 million by 2035; urinalysis reaches USD 911.6 million. Imaging reaches USD 2,061.5 million and benefits from software that can improve access to interpretation, provided clinical governance is maintained.

By Application

Bacteriology leads because it serves companion-animal infection workups and food-chain surveillance. Pathology grows with greater use of histology, cytology, and clinical pathology in oncology and complex disease. Parasitology grows fastest among the major applications as clinics and animal-health programs expand screening for intestinal, vector-borne, and herd-level parasitic disease. The mix makes speed, sample quality, and interpretation capacity as important as assay sensitivity.

By Animal Type

Companion animals are led by dogs at USD 2,298.0 million in 2025 and 8.9% CAGR, followed by cats at USD 1,085.1 million and 9.4%, horses at USD 446.9 million and 9.2%, and other companion animals at USD 319.5 million and 8.1%. The category's scale reflects repeated clinic interaction and relatively high diagnostic intensity.

Farm-animal demand is divided among cattle at USD 473.6 million in 2025 and 9.2% CAGR, swine at USD 270.7 million and 9.7%, poultry at USD 304.4 million and 9.5%, and other farm animals at USD 135.3 million and 8.3%. Swine and poultry growth is closely associated with surveillance-intensive production systems, while cattle demand combines herd health with movement and outbreak testing.

By End Use

Hospitals and clinics remain the central diagnostic decision point, while reference laboratories handle breadth and complexity. Zoetis's Louisville reference laboratory illustrates continued investment in scaled laboratory capacity. Home care grows fastest from a smaller base as glucose monitoring, simple screening, connected devices, and remote-care workflows extend participation beyond the clinic. Its growth should be interpreted as an expansion of monitoring and triage, not a substitute for veterinary diagnosis.

Technology growth also reveals a division of labor. Chemistry and ELISA remain foundational because they are deeply embedded in routine care and surveillance. Molecular testing and imaging gain share where specificity, urgency, or interpretive support creates a higher-value decision. Reference laboratories retain their role in complexity, even as point-of-care systems capture time-sensitive work. Suppliers that force an either-or choice risk missing the referral and follow-up pathways that link the two settings.

Veterinary Diagnostics Market Regional Analysis

North America

North America is the largest market, at USD 2,480.2 million in 2025 and USD 5,736.8 million in 2035. The U.S. accounts for USD 2,239.6 million, or 90.3% of regional revenue, and Canada accounts for USD 240.6 million, or 9.7%. Established companion-animal care, insurance growth, broad reference-laboratory access, and formal livestock surveillance support a high level of diagnostic intensity. The region's 8.8% CAGR is lower than Asia Pacific's, but it is built on a substantially larger installed base and mature recurring-consumable demand.

North American product revenue in 2025 is USD 1,267.9 million for consumables, USD 933.0 million for instruments, and USD 279.3 million for software. Lab-based testing represents USD 1,415.7 million and point-of-care testing USD 1,064.5 million. Clinical biochemistry is the largest technology at USD 630.5 million, while molecular diagnostics reaches USD 424.6 million and grows at 9.4%. By application, bacteriology is USD 982.6 million, pathology USD 680.1 million, and parasitology USD 546.1 million. Companion animals represent USD 1,925.1 million; farm animals represent USD 555.1 million. Hospitals and clinics are USD 1,188.5 million, reference laboratories USD 598.2 million, home care USD 439.5 million, and other end users USD 254.0 million.

Within North American clinical biochemistry, glucose monitoring is USD 292.0 million, blood gas and electrolyte analysis USD 188.6 million, and other tests USD 149.8 million. ELISA is USD 393.3 million within immunodiagnostics, compared with USD 40.2 million for lateral flow, USD 13.7 million for immunoassay analyzers, and USD 22.0 million for other tests. PCR is USD 271.2 million within molecular diagnostics; microarrays are USD 93.1 million and other tests USD 60.3 million. Dogs account for USD 1,062.7 million of companion-animal revenue, cats USD 499.9 million, horses USD 203.9 million, and other companion animals USD 158.6 million. Cattle represent USD 221.0 million of farm-animal revenue, swine USD 125.9 million, poultry USD 141.7 million, and other farm animals USD 66.4 million.

Europe

Europe reaches USD 1,221.4 million in 2025 and USD 2,928.8 million in 2035. Germany, the UK, France, Italy, Spain, and the Netherlands form the required country hierarchy. The region combines a large companion-animal population with cross-border disease-control rules and a dense base of diagnostics manufacturers and specialist laboratories. The Animal Health Law provides a common regulatory context, but country-level adoption still differs with practice structure, public laboratory funding, and pet-care spending. Germany and the UK provide deep clinical and laboratory markets; France and the Netherlands also contribute specialist diagnostics capacity; Italy and Spain offer sizable companion-animal and livestock use cases.

Asia Pacific

Asia Pacific is USD 1,072.1 million in 2025 and USD 2,640.9 million in 2035, the fastest-growing region at 9.5%. China, Japan, India, Australia, and South Korea are the prescribed country hierarchy. Growth combines expanding companion-animal care with persistent food-animal surveillance needs. China's domestic supply base is material: Mindray Animal Medical describes a portfolio spanning imaging, in-vitro diagnostics, monitoring, and surgical systems. ^{[7]Mindray Animal Medical - About Us - mindrayanimal.com} Japan and Australia have relatively developed companion-animal clinical markets; South Korea is receptive to rapid-testing and digital technologies; India's opportunity is more closely tied to expanding veterinary infrastructure and livestock health programs. Regional products must accommodate divergent laboratory access, cold-chain conditions, and customer affordability.

Latin America

Latin America grows from USD 336.0 million in 2025 to USD 789.0 million in 2035. Brazil, Mexico, and Argentina form the country hierarchy. Brazil and Argentina provide substantial livestock-related testing potential alongside growing urban companion-animal care, while Mexico links a large pet base with varied access to advanced services. Cost sensitivity and lower insurance penetration make affordable formats, distributor reach, and public laboratory participation more important than in North America. Growth therefore depends on converting disease surveillance and urban clinic demand into dependable testing workflows rather than on pet ownership alone.

Middle East and Africa

Middle East & Africa expands from USD 224.0 million in 2025 to USD 541.7 million in 2035. South Africa, Saudi Arabia, and the UAE form the country hierarchy. South Africa offers an established private-practice and livestock base. Saudi Arabia and the UAE have premium companion-animal and camelid use cases alongside animal-health surveillance requirements. The region's 9.3% CAGR reflects a small base and opportunities for field-deployable diagnostics, but uneven laboratory infrastructure and procurement capacity require differentiated go-to-market models.

Asia Pacific's 9.5% CAGR signals the strongest expansion opportunity, but not a uniform one. China, Japan, India, Australia, and South Korea differ sharply in clinical maturity, domestic manufacturing, infrastructure, and animal-health priorities. Successful suppliers will need to balance premium companion-animal systems with durable, field-ready molecular and surveillance products. Latin America and Middle East & Africa require an even tighter fit between test cost, distribution, and laboratory access; high disease relevance alone will not guarantee adoption.

Veterinary Diagnostics Market Share & Competitive Landscape

Competition is concentrated around integrated companion-animal ecosystems and diversified across livestock, poultry, equine, and specialty diagnostics. IDEXX and Zoetis have extensive companion-animal franchises, installed analyzers, and laboratory networks. IDEXX reported USD 3.898 billion in 2024 revenue, with Companion Animal Group revenue of USD 3.574 billion. Zoetis reported USD 9.3 billion in 2024 total revenue across its animal-health portfolio. ^{[8]Zoetis - Zoetis Reports Fourth Quarter and Full Year 2024 Results, 2025 - investor.zoetis.com} Their scale is strategically important because it supports product development, field service, laboratory infrastructure, and digital workflow integration.

Competitive advantage depends less on a single assay than on the ability to sustain a usable clinical system: test menu, analyzer reliability, consumable availability, software integration, technical support, and a credible route for complex samples. Specialist suppliers can compete effectively where livestock disease expertise, regional registration, or a narrow assay menu matters more than a broad companion-animal installed base. Consolidation and laboratory investment can strengthen network reach, but they also raise the importance of interoperability for practices that use multiple vendors.

Recent Industry Developments

• In June 2025, bioMérieux launched VETFIRE equine infectious respiratory disease testing on the BIOFIRE SPOTFIRE system.
• In 2025, Zoetis announced a new reference laboratory in Louisville, Kentucky, to expand access to cytology, chemistry, hematology, microbiology, and histology testing.
• In October 2025, IDvet launched ID Screen Strangles Double Antigen ELISA for equine serology.